USANA Health Sciences (NYSE:USNA) Issues FY 2026 Earnings Guidance

USANA Health Sciences (NYSE:USNA) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.760-0.760 for the period, compared to the consensus estimate of 2.120. The company issued revenue guidance of $910.0 million-$910.0 million, compared to the consensus revenue estimate of $945.1 million.

Analysts Set New Price Targets

USNA has been the subject of a number of analyst reports. Wall Street Zen raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. Zacks Research lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, USANA Health Sciences currently has an average rating of “Reduce”.

USANA Health Sciences Price Performance

Shares of USNA traded up $0.05 during trading hours on Tuesday, reaching $22.89. 123,607 shares of the company’s stock traded hands, compared to its average volume of 119,795. USANA Health Sciences has a twelve month low of $16.60 and a twelve month high of $32.32. The business’s fifty day simple moving average is $20.53 and its two-hundred day simple moving average is $19.77. The firm has a market capitalization of $422.53 million, a price-to-earnings ratio of 48.70, a P/E/G ratio of 0.87 and a beta of 0.73.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.50). The company had revenue of $223.27 million during the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. On average, equities research analysts expect that USANA Health Sciences will post 2.12 EPS for the current year.

Insider Activity at USANA Health Sciences

In related news, insider Joshua Foukas sold 3,791 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $19.82, for a total transaction of $75,137.62. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Brent Neidig sold 5,002 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total value of $97,288.90. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 17,660 shares of company stock valued at $336,579. Insiders own 0.82% of the company’s stock.

Institutional Investors Weigh In On USANA Health Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of USNA. National Bank of Canada FI boosted its position in shares of USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after purchasing an additional 1,201 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after purchasing an additional 1,901 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after purchasing an additional 1,327 shares in the last quarter. Parallel Advisors LLC lifted its stake in USANA Health Sciences by 1,354.3% during the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after purchasing an additional 3,589 shares during the last quarter. Finally, Quantbot Technologies LP lifted its stake in USANA Health Sciences by 19.5% during the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after purchasing an additional 646 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.